Q4 EPS Estimates for Bio-Techne Decreased by Leerink Partnrs

Bio-Techne Co. (NASDAQ:TECH - Free Report) - Equities researchers at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for shares of Bio-Techne in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.51 for the quarter, down from their previous forecast of $0.52. The consensus estimate for Bio-Techne's current full-year earnings is $1.68 per share.

Other analysts have also issued research reports about the company. Royal Bank of Canada raised their price target on Bio-Techne from $79.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 6th. StockNews.com raised Bio-Techne from a "hold" rating to a "buy" rating in a research report on Tuesday, November 12th. Robert W. Baird lifted their price target on Bio-Techne from $82.00 to $84.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. KeyCorp increased their price objective on Bio-Techne from $80.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Finally, Scotiabank boosted their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the company a "sector outperform" rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $86.57.

Bio-Techne Trading Down 1.0 %

Shares of NASDAQ TECH traded down $0.67 during trading hours on Monday, hitting $66.77. The company's stock had a trading volume of 1,766,103 shares, compared to its average volume of 1,289,279. The business has a 50-day simple moving average of $74.14 and a 200-day simple moving average of $74.11. The stock has a market cap of $10.61 billion, a price-to-earnings ratio of 67.44, a P/E/G ratio of 5.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 3.94. Bio-Techne has a 12 month low of $61.16 and a 12 month high of $85.57.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Shareholders of record on Monday, February 17th will be issued a $0.08 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $0.32 annualized dividend and a yield of 0.48%. Bio-Techne's dividend payout ratio (DPR) is presently 32.32%.

Insider Transactions at Bio-Techne

In other news, CEO Kim Kelderman sold 13,392 shares of the firm's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the sale, the chief executive officer now owns 39,004 shares of the company's stock, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 3.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group purchased a new stake in Bio-Techne during the 3rd quarter valued at $39,000. UMB Bank n.a. lifted its holdings in Bio-Techne by 46.4% in the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 168 shares during the period. Quest Partners LLC purchased a new position in Bio-Techne in the third quarter worth about $43,000. Mather Group LLC. grew its stake in shares of Bio-Techne by 51.5% during the 3rd quarter. Mather Group LLC. now owns 612 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 208 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its position in shares of Bio-Techne by 60.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 672 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 253 shares during the last quarter. Institutional investors own 98.95% of the company's stock.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.